Pegylated liposomal doxorubicin in recurrent malignant glioma: analysis of a case series

Oncology
Martin GlasP Hau

Abstract

Recurrent malignant glioma has a dismal prognosis, and therapeutic options are scarce. After previous potentially encouraging reports on liposomal pegylated doxorubicin (PEG-DOX) in this setting, PEG-DOX was applied to patients with recurrent malignant glioma in an institutional series. In a retrospective analysis, 49 patients with recurrent high-grade glioma (WHO III, n = 18; WHO IV, n = 31) were treated with PEG-DOX (days 1 and 14/28, 20 mg/m(2), n = 26) alone or in combination with temozolomide (days 1-5/28, 200 mg/m(2), n = 23). The response rate, progression-free survival and overall survival were evaluated. The rate of progression-free patients at 6 months after initiation of therapy was 27% (WHO III, 33%; WHO IV, 23%). The median overall survival (mOS) after initiation of PEG-DOX (monotherapy and combination therapy) was 8 months (WHO III, 16 months; WHO IV, 7 months). The mOS after initiation of PEG-DOX monotherapy was 8 months, and after initiation of combination therapy, 10 months. Both regimens were well tolerated, with the main side effect being hematologic toxicity (grade 1-2, 8%; grade 3-4, 18%). These data demonstrate the safety and moderate efficacy of PEG-DOX +/- temozolomide therapy in recurrent malignant glio...Continue Reading

References

Jul 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D R MacdonaldJ G Cairncross
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E T WongW K Yung
Apr 13, 2001·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M BradaS Zaknoen
Dec 12, 2003·Cancer·Peter HauAndreas Steinbrecher
Jan 28, 2004·Cancer·Susan M ChangMichael D Prados
Mar 5, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M E R O'BrienUNKNOWN CAELYX Breast Cancer Study Group
Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group

❮ Previous
Next ❯

Citations

Mar 20, 2010·Nature Reviews. Cancer·Daniel A TennantEyal Gottlieb
Nov 19, 2011·Drug Discovery Today·Luca Costantino, Diana Boraschi
Aug 19, 2015·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·James R WhittleMark A Rosenthal
Nov 18, 2020·Pharmaceutics·Huilong Luo, Eric V Shusta

❮ Previous
Next ❯

Related Concepts

Related Feeds

Astrocytes

Astrocytes are glial cells that support the blood-brain barrier, facilitate neurotransmission, provide nutrients to neurons, and help repair damaged nervous tissues. Here is the latest research.